Literature DB >> 2447292

Role of endogenous alpha/beta interferon in the selection of virus nonproducer Friend leukemia cells after serial intraperitoneal passages in syngeneic mice.

M Ferrantini1, F Belardelli, C Locardi.   

Abstract

Serial intraperitoneal passage of interferon (IFN)-sensitive Friend leukemia cells (FLCs) and L1210-S and RBL-5 tumor cells in syngeneic mice resulted in the selection of tumor cells exhibiting a marked decrease in the capacity to release reverse transcriptase (RT) activity. The virus nonproducer phenotype was a stable characteristic of clones derived from in vivo-passaged IFN-sensitive 745 FLCs. In contrast, in vivo passages of IFN-resistant 3Cl-8 FLCs and L1210-R cells did not result in any significant decrease in the capacity of these tumor cells to release in vitro RT activity. Although in vitro treatment of IFN-sensitive FLCs with mouse alpha/beta IFN (IFN-alpha/beta) for 1 or 10 passages resulted in a marked inhibition in the release of RT activity, these effects were completely reversible after removal of IFN from the culture medium. In addition, in vitro treatment of 745 FLCs with IFN resulted in a marked increase in the expression of H-2 (class I) and gp70 Friend virus antigens on the cell membrane. These effects were not observed in IFN-resistant 3Cl-8 cells. To investigate the possible role of endogenous IFN in the in vivo selection of virus nonproducer tumor cells, IFN-sensitive virus producer FLCs were serially passaged intraperitoneally in mice treated with antibodies to IFN-alpha/beta and in control mice, and the recovered tumor cells were cloned in vitro. Most (83 to 91%) of the clones derived from 745 cells recovered from control mice did not produce any detectable RT activity in the culture supernatants. In contrast, 96% of the clones (26 of 27) derived from 745 cells recovered from mice serially treated with antibodies to IFN-alpha/beta were still capable of releasing high levels of RT activity in the culture medium, indicating that endogenous IFN-alpha/beta was indeed an important host component for the in vivo selection of virus nonproducer tumor cell variants. The results reported in this article indicate that both direct effects of IFN on tumor cells and host-mediated effects are involved in this phenomenon.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447292      PMCID: PMC250574     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  ASSAY FOR FRIEND LEUKEMIA VIRUS: RAPID QUANTITATIVE METHOD BASED ON ENUMERATION OF MACROSCOPIC SPLEEN FOCI IN MICE.

Authors:  A A AXELRAD; R A STEEVES
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

2.  Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain.

Authors:  E Affabris; C Jemma; G B Rossi
Journal:  Virology       Date:  1982-07-30       Impact factor: 3.616

Review 3.  The murine sarcoma virus-induced tumor: exception or general model in tumor immunology?

Authors:  J P Levy; J C Leclerc
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

4.  Mouse peritoneal cells confer an antiviral state on mouse cell monolayers: role of interferon.

Authors:  E Proietti; S Gessani; F Belardelli; I Gresser
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

5.  Injection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus.

Authors:  F Belardelli; F Vignaux; E Proietti; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

6.  Friend erythroleukaemia cell mutants defective in viral gene expression.

Authors:  J Yokota; A Iwamoto; A Suzuki; S Yamaguchi-Tejima; Y Kitamura; H Yoshikura
Journal:  J Gen Virol       Date:  1984-02       Impact factor: 3.891

7.  Production of Friend leukaemia antigens in chronically-infected cells treated with interferon.

Authors:  C Ramoni; G B Rossi; G P Matarese; A Dole
Journal:  J Gen Virol       Date:  1977-11       Impact factor: 3.891

8.  Biologic and biochemical differences between in vitro and in vivo passaged Friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize.

Authors:  F Belardelli; M Ferrantini; C Maury; L Santurbano; I Gresser
Journal:  Int J Cancer       Date:  1984-09-15       Impact factor: 7.396

9.  Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors.

Authors:  I Gresser; F Belardelli; C Maury; M T Maunoury; M G Tovey
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

10.  Properties of cell lines derived from tumors induced by Friend virus in BALB/c and BALB/c-H-2b mice.

Authors:  H A Freedman; F Lilly
Journal:  J Exp Med       Date:  1975-07-01       Impact factor: 14.307

View more
  4 in total

1.  Studies on the expression of H-2 antigens in non-metastatic and highly metastatic Friend erythroleukemia cells: correlation with the in vivo behaviour of tumor cells.

Authors:  M Ferrantini; S Pulciani; E Proietti; G Lespinats; A Anastasi; V Ciolli; P Rizza; F Belardelli
Journal:  Clin Exp Metastasis       Date:  1989 Nov-Dec       Impact factor: 5.150

2.  Influence of the site of tumor growth on the capacity of a low tumorigenic line of Friend erythroleukemia cells to differentiate.

Authors:  I Gresser; J Moss; D Woodrow; C Le Bousse; C Maury; E Proietti; F Belardelli
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

3.  Increased human immunodeficiency virus (HIV) expression in chronically infected U937 cells upon in vitro differentiation by hydroxyvitamin D3: roles of interferon and tumor necrosis factor in regulation of HIV production.

Authors:  C Locardi; C Petrini; G Boccoli; U Testa; C Dieffenbach; S Buttò; F Belardelli
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Persistent infection of normal mice with human immunodeficiency virus.

Authors:  C Locardi; P Puddu; M Ferrantini; E Parlanti; P Sestili; F Varano; F Belardelli
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.